SEQUOIA Arm C (Zanubrutinib for Del[17p] Treatment-Naive [TN]-CLL/SLL) and Arm D (Zanubrutinib + Venetoclax for TN-CLL/SLL)

home / between-the-lines / sequoia-arm-c-zanubrutinib-for-del-17p-treatment-naive-tn-cll-sll-and-arm-d-zanubrutinib

Experts discuss the critical advancements in biomarker-driven frontline treatment for high-risk chronic lymphocytic leukemia (CLL), emphasizing the SEQUOIA trial’s evidence supporting targeted Bruton tyrosine kinase inhibitor monotherapy and combination therapies with venetoclax as effective, personalized, and well-tolerated options that improve progression-free survival and patient quality of life.

2 KOLs are featured in this series.

EP. 1: Zanubrutinib Monotherapy in Patients With Del(17p) and Treatment-Naive CLL/SLL (SEQUOIA Arm C)

Andrew H Lipsky, MD
September 29th 2025

Experts discuss the critical role of biomarker testing in guiding frontline treatment decisions for chronic lymphocytic leukemia (CLL)—especially in high-risk patients with TP53 mutations or deletion 17p—and highlight promising 5-year outcomes from the SEQUOIA trial, which supports targeted monotherapy as an effective alternative to chemoimmunotherapy in this population.